TGF-beta 1/1.2 Antibody

Catalog #: AB-101-NA
6 Citations Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
AB-101-NA

TGF‑ beta 1 Inhibition of IL‑4-dependent Cell Proliferation and Neutralization by TGF‑ beta 1/1.2 Antibody.

1 Image

Product Details

Citations (6)

Supplemental Products

Reviews

Summary Data Examples Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

TGF-beta 1/1.2 Antibody Summary

Specificity

Detects TGF‑ beta 1/1.2 in direct ELISAs and Western blots. In direct ELISAs and Western blots, less than 10% cross-reactivity with recombinant amphibian TGF‑ beta 5 is observed and less than 2% cross-reactivity with recombinant human TGF‑ beta 3, recombinant chicken TGF‑ beta 3, and porcine TGF‑ beta 2 is observed.

Source

Polyclonal Chicken IgY

Purification

Ion exchange-purified from egg yolks

Immunogen

Chinese hamster ovary cell line CHO-derived recombinant human TGF‑ beta 1 (R&D Systems, Catalog # 240-B)
Ala279-Ser390
Accession # P01137

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.

Endotoxin Level

<0.10 EU per 1 μg of the antibody by the LAL method.

Label

Unconjugated

Purity

Ion exchange-purified from egg yolks

Applications

Recommended Concentration

Sample

Western Blot

1 µg/mL

Recombinant Human TGF-beta 1 (Catalog # 240-B)
Recombinant Human TGF-beta 1.2 (Catalog # 304-B3)

Neutralization

Measured by its ability to neutralize TGF‑ beta 1 inhibition of IL‑4-dependent proliferation in the HT‑2 mouse T cell line [Tsang, M. et al. (1995) Cytokine 7:389]. The Neutralization Dose (ND₅₀) is typically 0.2-0.6 µg/mL in the presence of 0.25 ng/mL Recombinant Human TGF‑ beta 1 and 7.5 ng/mL Recombinant Mouse IL‑4.

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Neutralization

View Larger

TGF‑ beta 1 Inhibition of IL‑4-dependent Cell Proliferation and Neutralization by TGF‑ beta 1/1.2 Antibody. Recombinant Human TGF-beta 1 (Catalog # 240-B) inhibits Recombinant Mouse IL-4 (Catalog # 404-ML) induced proliferation in the HT-2 mouse T cell line in a dose-dependent manner (orange line). Inhibition of Recombinant Mouse IL-4 (7.5 ng/mL) activity elicited by Recombinant Human TGF-beta 1 (0.25 ng/mL) is neutralized (green line) by increasing concentrations of Chicken Anti-TGF-beta 1/1.2 Polyclonal Antibody (Catalog # AB-101-NA). The ND₅₀ is typically 0.2-0.6 µg/mL.

Reconstitution Calculator

Preparation and Storage

Reconstitution

Reconstitute at 1 mg/mL in sterile PBS.

Shipping

The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: TGF-beta 1/1.2

TGF-beta 1 (transforming growth factor beta 1) is one of three closely related mammalian members of the large TGF-beta superfamily that share a characteristic cystine knot structure. TGF-beta 1, -2 and -3 are highly pleiotropic cytokines that are proposed to act as cellular switches that regulate processes such as immune function, proliferation and epithelial-mesenchymal transition. Each TGF-beta isoform has some non-redundant functions; for TGF-beta 1, mice with targeted deletion show defects in hematopoiesis and endothelial differentiation, and die of overwhelming inflammation. Human TGF-beta 1 cDNA encodes a 390 amino acid (aa) precursor that contains a 29 aa signal peptide and a 361 aa proprotein. A furin-like convertase processes the proprotein to generate an N-terminal 249 aa latency-associated peptide (LAP) and a C-terminal 112 aa mature TGF- beta 1. Disulfide-linked homodimers of LAP and TGF-beta 1 remain non-covalently associated after secretion, forming the small latent TGF-beta 1 complex. Covalent linkage of LAP to one of three latent TGF-beta binding proteins (LTBPs) creates a large latent complex that may interact with the extracellular matrix. TGF-beta is activated from latency by pathways that include actions of the protease plasmin, matrix metalloproteases, thrombospondin 1 and a subset of integrins. Mature human TGF-beta 1 shares 100% aa identity with pig, dog and cow TGF-beta 1, and 99% aa identity with mouse, rat and horse TGF-beta 1. It demonstrates cross-species activity. TGF-beta 1 signaling begins with high-affinity binding to a type II ser/thr kinase receptor termed TGF-beta RII. This receptor then phosphorylates and activates a second ser/thr kinase receptor, TGF-beta RI (also called activin receptor-like kinase (ALK) -5), or alternatively, ALK‑1. This complex phosphorylates and activates Smad proteins that regulate transcription. Contributions of the accessory receptors betaglycan (also known as TGF-beta RIII) and endoglin, or use of Smad-independent signaling pathways, allow for disparate actions observed in response to TGF-beta in different contexts.

Long Name

Transforming Growth Factor beta 1 and 1.2

Entrez Gene IDs

7040 (Human); 21803 (Mouse); 59086 (Rat)

Alternate Names

TGFb1.2; TGF-beta 1/1.2

Product Datasheets

Product Datasheet

COA

SDS

Related Research Areas

Citations for TGF-beta 1/1.2 Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

6 Citations: Showing 1 - 6
Filter your results:

Filter by:

IFNgamma-primed periodontal ligament cells regulate T-cell responses via IFNgamma-inducible mediators and ICAM-1-mediated direct cell contact
Authors: W Singhatana, S Kitpakorns, M Toso, P Pavasant
Royal Society open science, 2022-07-27;9(7):220056.
Species: Human
Sample Types: Whole Cells
Applications: Neutralization
The Effect of TGF-beta1 Reduced Functionality on the Expression of Selected Synaptic Proteins and Electrophysiological Parameters: Implications of Changes Observed in Acute Hepatic Encephalopathy
Authors: M Popek, B Bobula, K Orze?-Gajo, M Zieli?ska
International Journal of Molecular Sciences, 2022-01-19;23(3):.
Species: Mouse
Sample Types: In Vivo
Applications: Neutralization
Early expansion of myeloid-derived suppressor cells inhibits SARS-CoV-2 specific T-cell response and may predict fatal COVID-19 outcome
Authors: A Sacchi, G Grassi, V Bordoni, P Lorenzini, E Cimini, R Casetti, E Tartaglia, L Marchioni, N Petrosillo, F Palmieri, G D'Offizi, S Notari, M Tempestill, MR Capobianch, E Nicastri, M Maeurer, A Zumla, F Locatelli, A Antinori, G Ippolito, C Agrati
Cell Death Dis, 2020-10-27;11(10):921.
Species: Human
Sample Types: Whole Cells
Applications: Neutralization
Cancer associated fibroblasts regulate keratinocyte cell-cell adhesion via TGF-ï¿½-dependent pathways in genotype-specific oral cancer
Authors: S S Prime
Carcinogenesis, 2016-11-01;0(0):.
Species: Human
Sample Types: Cell Culture Supernates
Applications: Neutralization
Cord blood mesenchymal stem cells suppress DC-T Cell proliferation via prostaglandin B2.
Authors: van den Berk L, Jansen B, Snowden S, Siebers-Vermeulen K, Gilissen C, Kogler G, Figdor C, Wheelock C, Torensma R
Stem Cells Dev, 2014-04-23;23(14):1582-93.
Species: Human
Sample Types: Whole Cells
Applications: Neutralization
Isoform specificity of commercially-available anti-TGF-beta antibodies.
Authors: Mozes MM, Hodics T, Kopp JB
J. Immunol. Methods, 1999-05-27;225(1):87-93.
Species: Human
Sample Types: Recombinant Protein
Applications: Western Blot